In cancer research, NGS helps in the identification of variations and mutations. Therefore, researchers and clinicians use the NGS or Next Generation Sequencing (NGS) Clinical Assays to examine the DNA and RNA portions for cardiovascular disorders. They identify the abnormalities that may be related to the disease.
Pros of Next-Generation Sequencing in Medicine
- It is Faster
The next-generation sequencing provides more data in a short amount of time. The researchers can sequence the entire genome or parts of the genome that causes the disease. Other tools usually sequence the DNA in small sections. It takes years to sequence the whole genome, whereas, with NGS, it will take around a week.
The researchers will combine next-generation sequencing with signal detection. Earlier, it was done in combination with signal detection as a separate process.
- Cost Effective
Using Next Generation Sequencing (NGS) Clinical Assays to diagnose, assess and treat cancer at low costs is one of the best developments in oncology. It is sometimes partially or fully covered by the insurance companies.
- Need Fewer Samples
You only need fewer samples to get the desired data. More data is generated using fewer samples throughout the sequencing.
Next-Generation Sequencing in Clinical Oncology
- Accurately Detect Genetic Mutation
The Next Generation Sequencing Clinical Assays, or NGS, allow experts to detect genes linked to tumour formation and progression reliably. It is a high-sensitivity case and makes an excellent choice for detecting infrequent mutations.
The data has set targets to produce the most accurate and personalised results for the patient. There are instances where NGS could identify BRCA1 and BRCA2 genes variants provided it is present in >10% of a tissue sample. Such tests help to make better decisions to treat cancer patients.
- Precision Diagnostics
Next-generation sequencing (NGS) has emerged as a useful method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors as genomics-focused pharmacology begins to play a greater role in cancer treatment. NGS-driven companion diagnostics are widely considered to be the driving force behind the selection of treatments in the future to maximize patient outcomes as targeted therapies become the new standard of care in oncology.
NGS with the Whole Exome Sequencing (WES) Panel has the potential to have a significant impact on oncology because it offers advantages in accuracy, sensitivity, and speed over conventional methods. It is unnecessary to order multiple tests in order to locate the underlying mutation because NGS can evaluate multiple genes with a single assay.
The time it takes to respond is cut in half with this multigene strategy, making it a more cost-effective option and lowering the possibility of wasting precious clinical samples. Additionally, NGS on the oncology panels has the potential to offer high sensitivity, making it possible to identify mutations in as little as 5% of the DNA that is isolated from a tumour sample.
